234 related articles for article (PubMed ID: 12027116)
1. Refractory obsessive-compulsive disorder: state-of-the-art treatment.
Hollander E; Bienstock CA; Koran LM; Pallanti S; Marazziti D; Rasmussen SA; Ravizza L; Benkelfat C; Saxena S; Greenberg BD; Sasson Y; Zohar J
J Clin Psychiatry; 2002; 63 Suppl 6():20-9. PubMed ID: 12027116
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder.
Marazziti D; Pallanti S
Am J Psychiatry; 1999 Nov; 156(11):1834-5. PubMed ID: 10553756
[No Abstract] [Full Text] [Related]
4. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.
Poyurovsky M; Kurs R; Weizman A
J Clin Psychiatry; 2003 May; 64(5):611. PubMed ID: 12755669
[No Abstract] [Full Text] [Related]
5. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
[No Abstract] [Full Text] [Related]
8. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
Francobandiera G
Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
[TBL] [Abstract][Full Text] [Related]
9. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.
Bloch MH; Storch EA
J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):251-62. PubMed ID: 25791142
[TBL] [Abstract][Full Text] [Related]
10. The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent.
Pathak S; Cottingham EM; McConville BJ
J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S93-4. PubMed ID: 12880505
[No Abstract] [Full Text] [Related]
11. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.
Bogetto F; Bellino S; Vaschetto P; Ziero S
Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
13. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
Weimer E; Braus DF; Cavus I; Thome J
Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
Poyurovsky M; Dorfman-Etrog P; Hermesh H; Munitz H; Tollefson GD; Weizman A
Int Clin Psychopharmacol; 2000 May; 15(3):169-73. PubMed ID: 10870875
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
17. Obsessive compulsive disorder.
Soomro GM
Clin Evid; 2005 Dec; (14):1270-83. PubMed ID: 16620454
[No Abstract] [Full Text] [Related]
18. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
19. [Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder].
Vloet TD; Simons M; Herpertz-Dahlmann B
Z Kinder Jugendpsychiatr Psychother; 2012 Jan; 40(1):29-39; quiz 39-40. PubMed ID: 22161940
[TBL] [Abstract][Full Text] [Related]
20. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
